Tropifexor, also known as LJN452, is a farnesoid X receptor agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced into phase 2 human clinical trials in patients with NASH and PBC.
Chemical Name:
2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
Chemical Properties:
Boiling point: 700.0±65.0 °C(Predicted)
density: 1.55±0.1 g/cm3(Predicted)
pka: 3.84±0.10(Predicted)
FXR Agonists Related Products:
Turofexorate isopropyl; T0901317; Obeticholic Acid